Skip to main content
Premium Trial:

Request an Annual Quote

The R&D Version of Musical Chairs

Martin Mackay is leaving his spot as the head of research and development at Pfizer to join AstraZeneca, where he will serve in the same capacity, reports Fierce Biotech. The Wall Street Journal's Health Blog adds that Mackay shared that spot at Pfizer with Mikael Dolsten, who was head of R&D at Wyeth, and Dolsten will now be the sole person leading that section at Pfizer. The R&D position at AstraZeneca that Mackay is taking is new, and he will have the drug discovery and drug development section reporting to him. "Martin's appointment to this new role will provide a single point of senior accountability as we continue to make the changes necessary to improve the productivity and efficiency of our research and development organization," says AstraZeneca CEO's David Brennan in a statement.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.